Remote Jobs at Atsena Therapeutics

Atsena Therapeutics

11 - 50 employees

🧬 Biotechnology

🏥 Healthcare

💰 $150M Series C - Atsena Therapeutics on 2025-04

Biotechnology • Healthcare

Atsena Therapeutics is a clinical-stage gene therapy company developing first- and best-in-class treatments for inherited retinal diseases. Its lead program, ATSN-201, is in a pivotal Phase 3 trial for X-linked retinoschisis (XLRS); other programs include ATSN-101 for LCA1 (pivotal trial planned), and earlier-stage assets targeting Usher Syndrome 1B and Stargardt disease. Atsena uses proprietary AAV-based delivery platforms — notably the laterally spreading capsid AAV. SPR and a dual vector technology — engineered to address retinal delivery challenges and to enable larger gene payloads. The company focuses on advancing ocular gene therapies through clinical development.